Therapeutic Efficacy and Clinical Application of Rasburicase in Tumor Lysis Syndrome
Elitek exerts its therapeutic effect by catalyzing the oxidation of uric acid into allantoin, a more soluble metabolite, thereby mitigating hyperuricemia and reducing the risk of urate nephropathy or acute kidney injury in TLS. Clinical trials demonstrated rapid uric acid reduction within 4 hours post-administration, with 92%-100% of patients achieving and maintaining uric acid levels ≤7.5 mg/dL within 96 hours. In randomized studies, Elitek significantly outperformed allopurinol in uric acid AUC reduction (128 vs. 328 mg·hr/dL) and response rates (87% vs. 66%). Efficacy was consistent across pediatric and adult populations, though children <2 years exhibited slightly lower response rates. The drug is administered as a 0.2 mg/kg/day IV infusion for ≤5 days, with no recommended repeat courses. TLS incidence remained low (3%-4%) across treatment arms. Contraindications include G6PD deficiency due to risk of hemolysis and methemoglobinemia. Long-term outcomes or survival benefits are not specified in the description.
